innoHealth has been granted with the SME Instrument Phase I by the European Comission

The European Comission has granted to innoHealth Group with the financial support to develop the Phase II of SkinXCare, Integral cell-biology platform for the development of the first effective treatment of radiodermatitis. It is included in the call SME Instrument 05-2016-2017 of the EU. The Project 743887 has a budget of 50.000 € to prepare the Phase II. ec_for_fb